Our Ref: 578/2023 November 2023



## Re: Your request made under the Freedom of Information Act 2000

Q1. Please provide the total number of patients treated in the last 6 months for:

- Polycythaemia Vera (ICD10 code D45)
- Myelofibrosis (ICD10 code D47.4)
- Myelofibrosis (ICD10 code D47.4) patients aged 65 and older

Unfortunately the numbers for within the last 6 months (as in question 1) are too low for us to provide, due to data protection limitations.

- Q2. How many patients were treated in the past 6 months (for any disease) with:
- Ruxolitinib 16
- Fedratinib 0
- Interferon (any type) -17

•

Q3. Of the patients treated in the past 6 months with Ruxolitinib, how many patients had a diagnosis for:

- Polycythaemia Vera (ICD10 code D45)
- Myelofibrosis (ICD10 code D47.4)

Our pharmacy system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.

## Q4. How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?

- Of these patients, how many were treated in the past 6 months with Hydroxycarbamide?
- Of these patients, how many were treated in the past 6 months with Interferon therapy?
- Of these patients, how many have received no active treatment in the past 6 months?

Our pharmacy system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.

Answer below.

## Q5. How many Polycythaemia Vera (ICD10 code D45) patients has your trust diagnosed in the past 3 years?

- Of these patients, how many were treated in the past 6 months with Hydroxycarbamide?
- Of these patients, how many were treated in the past 6 months with Interferon therapy?

Our pharmacy system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.

Answer below.

Q6. Does your trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part.

Our Ref: 578/2023 November 2023



The number of distinct patients treated at the trust for the first time with the two conditions in the relevant timespans & age ranges as requested in questions 4 and 5 are provided below. Note that the latest available snapshot is as at 31/10/2023, and thus the date range is 01/11/2020 to 31/10/2023:

Question	Answer
4. D474 last 3 years:	20
5. D45 last 3 years:	22